Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro

Fig. 1

Her-2/neu-specific CD8+ T cells are efficiently expanded out by Her-2/neu-loaded T2 cells from advanced breast cancer patients. a In vitro Her-2/neu-specific CD8+ T cells were expanded out by Her-2/neu-loaded T2 cells in addition with rhIL-2 and irradiated autologous PBMC (peptides, HER-2/neu(39–47), HER-2/neu(369–377), and HER-2/neu(435–443), respectively). Left, proliferation assessed as uptake of [3H] thymidine; right, total cell number counting of specific CD8+ T cells after expansion. Nearly 1.0E + 07 Her-2/neu-specific CTLs were expanded out in 8 weeks. b Her-2/neu-specific CD8+ T cells were verified by Her-2/neu-conjugated HLA-A*0201 Dextramer staining by fluoresence. Her-2/neu(369–377)- and Her-2/neu(435–443)-loaded T2 cells expanded out specific CD8+ T cells with the purity of around 85%. c The expanded Her-2/neu specific CD8+ T cells expressed massive activation makers CD25, CD40, and CD40L. The results are all from one representative of three independent experiments

Back to article page